• 1.The same criteria were applied to trials of fibrates, yielding seven trials. Six of them involved monotherapy with clofibrate, gemfibrozil, bezafibrate, or fenofibrate. The seventh was the ACCORD Lipid study that tested a combination of fenofibrate plus simvastatin versus the statin drug and placebo.

    应用同样的标准,开展贝特类药物的七项试验。其中六项试验涉及安妥明、吉非罗齐、苯扎贝特或非诺贝特的单一疗法。第七项试验是ACCORD脂质研究,测定非诺贝特联合辛伐他汀组合vs. 他汀类药物和安慰剂。

    来自 论坛

  • 2.Many medications cause dyspepsia, including aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics (metronidazole,macrolides), diabetes drugs (metformin,-glucosidase inhibitors, amylin analogs, GLP-1 receptor antagonists), antihypertensive medications (angiotensin-converting enzyme [ACE] inhibitors, angiotensin-receptor blockers), cholesterol-lowering agents (niacin, fibrates), neuropsychiatric medications (cholinesterase inhibitors [donepezil, rivastigmine]), SSRIs (fluoxetine, sertraline), serotonin-norepinephrine-reuptake inhibitors (venlafaxine, duloxetine), Parkinson drugs (dopamine agonists, monoamine oxidase [MAO]-B inhibitors), corticosteroids, estrogens, digoxin, iron, and opioids.

    多数药物可造成消化不良,包括阿司匹林,NSAIDs ,抗生素(甲硝唑,大环内酯类),糖尿病药物(二甲双胍,葡糖苷酶抑制剂,淀粉不溶素类似物,GLP-1受体拮抗剂),抗高血压药(血管转化酶抑制剂,血管紧张素受体抑制剂),降胆固醇药物(尼亚新,贝丁酸类),神经精神系统药物(胆碱酯酶抑制剂[多奈哌齐,卡巴拉汀]),选择性5羟色胺再吸收抑制剂(氟西汀,舍曲林),肾上腺素回收抑制剂(文拉法辛,度洛西汀),帕金森药物(多巴胺受体激动药,单胺氧化酶-B抑制剂), 皮质甾类,雌激素类,地高辛,铁剂和类罂粟碱。

    来自 论坛

  • 3."Although the observed changes in lipid parameters in statin-treated patients were modest, increases of a similar magnitude in HDL-related parameters for other therapies, such as statins and fibrates, have reduced adverse clinical outcomes and exerted a beneficial effect on the progression of atherosclerosis," Nicholls et al explain. "The most striking effect of RVX-208 was elevation of the concentration of larger HDL particles," which has been shown to be a strong predictor of cardiovascular protection in population studies. Since there was no observed plateau of efficacy, "further incremental benefit may be observed during longer duration of treatment. This would be consistent with the experience of many other agents that raise HDL-C," the authors predict.


    来自 论坛

  • 4.Fibrates are a class of medicines that have been in use for many years to lower level of lipids such as triglycerides and cholesterol in the blood。They were first subject to a Europe-wide review in 2005, when the CHMP's Pharmacovigilance Working Party reviewed their benefits and risks because of limited evidence of their long-term benefits in reducing cardiovascular risks. At that time the Working Party concluded that these medicines continued to have a place in the treatment of lipid disorders but should not be used as first-line treatment。


    来自 论坛